Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic acid to prevent ART-related bone mineral density loss in treatment-naive adults with HIV receiving non-TDF antiretroviral therapy
MOH_2025-11-04_015429Phase 4Recruiting
- Sponsor
- דר' עינת קדם
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of zoledronic acid in osteopenia, osteoporosis and human immunodeficiency virus infection (HIV) (4 arms), sponsored by דר' עינת קדם. Primary endpoint: Change in bone mineral density. Started Sep 2025; status: recruiting.
02
Drugs
zoledronic acid
03
Conditions
osteopeniaosteoporosishuman immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on MOH_2025-11-04_015429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-11-04_015429.